| Patient | Charlotte Brontë |
|---|---|
| Date of birth | 1816-04-21 |
| Identifiers | MRN HR-NI025-SYN-TD; SSN (made up) 000-25-3804 |
| Document date | 1855-02-24 |
| Author | Eleanor Thwaite, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Prenatal visit at 13 weeks with the nuchal translucency scan. [S]
Ms. Brontë returns at 13 weeks 1 day. She vomits two or three times a week and eats three meals and two snacks a day. She has taken ondansetron about twice a day this week and doxylamine-pyridoxine four tablets a day. Constipation has settled with diet. Her PUQE-24 score is 7. She has begun writing again in the mornings. The cell-free DNA result came back last week as low risk for trisomies 21, 18, and 13. She had the nuchal translucency scan this morning. She has had no headache, pain, or bleeding. [S]
| Element | Detail |
|---|---|
| Interval change | Vomiting two or three times a week; three meals and two snacks a day |
| PUQE-24 | 7 (moderate), down from 9 |
| Screening | Cell-free DNA low risk; nuchal translucency scan today |
| Function | Writing again in the mornings |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Morning nausea; vomiting two or three times a week; bowels regular |
| Neurological | Negative | No headache |
| Genitourinary | Negative | No bleeding or urinary symptoms |
| Psychiatric | Negative | Mood better; enjoying writing again |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe) | One tablet by mouth daily | Oral route | 1855-01-13 | active | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtime | Two tablets by mouth at bedtime | Oral route | 1855-01-13 to 1855-01-20 | completed | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day) | One tablet in the morning, one mid-afternoon, and two at bedtime | Oral route | 1855-01-20 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before meals | One tablet by mouth three times a day, 30 minutes before meals | Oral route | 1855-01-20 to 1855-01-29 | completed | S |
| Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours | 1000 mL over 8 hours, guided by daily electrolytes | Intravenous route | 1855-01-29 to 1855-02-01 | completed | S |
| Thiamine 100 mg intravenously daily, the first dose before any dextrose | 100 mg intravenously once daily; first dose before any dextrose-containing fluid | Intravenous route | 1855-01-29 to 1855-02-01 | completed | S |
| Ondansetron 4 mg intravenously every 8 hours | 4 mg by slow intravenous injection every 8 hours | Intravenous route | 1855-01-29 to 1855-02-01 | completed | S |
| Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg) | 20 mg (0.2 mL) subcutaneously once daily while in hospital | Subcutaneous route | 1855-01-29 to 1855-02-01 | completed | S |
| Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once | 2 g intravenously over 1 hour, one dose | Intravenous route | 1855-01-29 to 1855-01-29 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours | One tablet on the tongue every 8 hours | Oral route | 1855-02-01 to 1855-02-24 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea | One tablet on the tongue up to every 8 hours if needed | Oral route | 1855-02-24 to 1855-03-24 | completed | S |
| Thiamine 100 mg oral tablet, one tablet by mouth three times a day | One tablet by mouth three times a day while intake is poor | Oral route | 1855-02-01 to 1855-02-24 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 1855-02-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1855-02-24 | Body height | 152 | cm | S |
| 1855-02-24 | Body weight | 44.4 | kg | S |
| 1855-02-24 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 1855-02-24 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1855-02-24 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1855-02-24 | Heart rate | 82 | /min | S |
| 1855-02-24 | Respiratory rate | 14 | /min | S |
| 1855-02-24 | Body temperature | 36.6 | Cel | S |
| 1855-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1855-02-24 | Fetal Crown Rump length US | 70 | mm | Consistent with 13 weeks 1 day by the dating scan | Normal | S |
| 1855-02-24 | Fetal nuchal translucency measured by US | 1.5 | mm | <=3.5 mm | Normal | S |
Vital signs recorded on 1855-02-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 44.4 kg |
| Abdomen | Soft; uterus palpable above the pubic bone |
| Fetal | Scan this morning: single live fetus, crown-rump length 70 mm, nuchal translucency 1.5 mm, nasal bone present, no structural abnormality seen |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 day | active | confirmed | O09.519 | S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019). |
| Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarum | resolved | confirmed | O21.9 | S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R. |
| Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14 | active | confirmed | O21.1 | S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis. |
| Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment needed | active | confirmed | O99.281 | S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PUQE-24 score (recorded in the note; no LOINC code found) | Every visit while nausea and vomiting last | Completed today | 7 (moderate), down from 9 |
| Examination | Weight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydration | Every visit while nausea and vomiting last | Completed today | 44.4 kg, up 0.8 kg; pulse 82 |
| Laboratory | Electrolytes, urea nitrogen, creatinine, and glucose | Until stable on oral intake | Not indicated | Not repeated: normal two weeks ago and now eating regular meals |
| Imaging | Nuchal translucency scan | Once at 11 to 14 weeks, as she chose | Completed today | Crown-rump length 70 mm; nuchal translucency 1.5 mm |
| Laboratory | Cell-free DNA screening | From 10 weeks | Completed today | Low risk for trisomies 21, 18, and 13, received last week |
| Laboratory | TSH and free T4 | In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressed | Due | Repeat planned at 16 to 18 weeks |
| Medication safety | Antiemetic effects | Every visit and after each change | Completed today | Constipation settled; ondansetron changed to as needed; thiamine stopped |
| Medication safety | Low-dose aspirin | Start at 12 to 16 weeks with risk factors; review at every visit | Completed today | Started today at 81 mg at bedtime; bleeding precautions given |
| Examination | Blood pressure | Every prenatal visit | Completed today | 106/66 mmHg; baseline for aspirin and preeclampsia surveillance |
| Examination | Fetal heart | Every prenatal visit | Completed today | Live fetus on today's scan |
Goal progress:
Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021)
Follow-up: Prenatal visit at 17 weeks, with TSH and free T4. Next scheduled visit 1855-03-24: prenatal visit at 17 weeks: nausea and vomiting review and thyroid recheck. [S]